The phase I NiCOL trial (NCT03298893) [52] explored the anti-PD-1 nivolumab concurrent and following CCRT in 21 patients with stages IB2 to IVA locally advanced cervical cancer, regardless of lymph node status. This evidence concerns the gene PDCD1 and cervical cancer.